IIFL Securities's Stock Pick Today: Buy Aurobindo Pharma with Target Rs 1295
IIFL Securities has issued a buy call for Aurobindo Pharma, with a target price of Rs 1295. This represents a potential upside of over 2.5% from the current market price of Rs 1261.85. The brokerage firm cites the company's strong growth prospects and its attractive valuations as reasons for its bullish outlook. Aurobindo Pharma is one of India's leading pharmaceutical companies, with a presence in over 90 countries. The company manufactures a wide range of generic and branded drugs, and is also involved in biotechnology.
About Aurobindo Pharma:
Aurobindo Pharma Limited is a multinational pharmaceutical company based in Hyderabad, India. It is primarily engaged in the development, manufacture, distribution and marketing of a wide range of generic pharmaceuticals and active pharmaceutical ingredients (APIs) globally. Aurobindo Pharma has over 9,000 employees worldwide and operates in more than 150 countries. The company has a strong focus on API manufacturing and has one of the largest API production capacities in the world. Its product portfolio includes antibiotics, anti-retrovirals, anti-diabetics, cardiovascular and central nervous system drugs. Aurobindo Pharma is listed on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) in India.
52 Week Price Trend:
Aurobindo Pharma (NSE: AUROPHARMA) is currently trading at Rs 1261.85, close to its 52-week high of Rs 1177.1. This represents a significant increase from its 52-week low of Rs 443.15. Aurobindo Pharma's strong performance can be attributed to factors such as its wide product portfolio, manufacturing capabilities, and presence in emerging markets. The company's focus on innovation and R&D has also contributed to its growth. Despite facing some challenges in recent years, Aurobindo Pharma remains a leading player in the pharmaceutical industry and is expected to continue performing well in the future.
Stratzy's MOST Analysis:
Auropharma has been rated AA- by Stratzy's MOST framework. This rating is derived from the company's strong management team, positive outlook for growth, financial safety, and positive trend in its stock price. The AA- rating indicates that Auropharma has low fundamental risks and is a relatively safe investment. The company's strengths include its strong product portfolio, experienced management team, and robust financial position. Auropharma is well-positioned to continue growing in the future and is a good choice for investors seeking long-term returns.
Company's Fundamentals:
Aurobindo Pharma (NSE: AUROPHARMA) is a reputable pharmaceutical company with a stock price that has exhibited steady growth. Its key financial indicators are as follows: Stock PE (Price-to-Earnings) ratio of 21.77, indicating that investors are willing to pay 21.77 times the company's annual earnings per share. PB Ratio (Price-to-Book) of 2.17, suggesting that the company is currently valued at 2.17 times its net asset value. Dividend Yield of 0.43%, indicating that investors receive an annual dividend of 0.43% on their investment in Aurobindo Pharma shares.
Fundamental and Technical information provided in this blog were last updated on 05 Jun, 2024
Disclaimer: The information and recommendations presented in this section, including any attached reports, are sourced from third-party providers through diverse channels. The views and opinions expressed within these materials belong solely to their respective creators. These views and opinions do not necessarily reflect the position of Stratzy Fintech Pvt Ltd. Stratzy explicitly disclaims any guarantees, express or implied, regarding the accuracy and reliability of the provided content. We strongly advise consulting with a licensed financial advisor before making any investment decisions based on this information. Remember, seeking independent financial advice is crucial.